Depomed demands $105M from Esprit Pharma
Depomed is demanding more than $105 million from Esprit Pharma to satisfy claims that Esprit violated their licensing deal on ProQuin XR for urinary tract infections. Depomed says Esprit failed to make a $10 million milestone payment due December 15, among other things. Depomed of Menlo Park, CA is also demanding binding arbitration to settle its claims.
- see the release on the damages claim
Related Article:
Esprit adds $91M in VC. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
